Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventive nebivolol for left ventricular dysfunction in children with Duchenne muscular dystrophy
2010-020047-12Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) and left ventricular systolic dysfunction (LVSD) comparing Nebivolol (Temerit) with Placebo (2 arms). Primary endpoint: Left ventricular ejection fraction < 45% during follow-up. Started Apr 2011; status: completed.
02
Drugs
nebivolol
03
Conditions
Duchenne muscular dystrophy (DMD)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on 2010-020047-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020047-12.